* CEL-SCI Corp., Alexandria, Va., submitted an investigational newdrug application with the FDA to conduct a Phase I/II trial to testMultikine, a combination of a number of human cytokines derivedfrom human peripheral blood, as a potential treatment for advancedhead and neck cancer patients. The study will involve up to 30 patients.* Dyad Pharmaceuticals Corp., Columbia, Md., received a $500,000Phase II Small Business Innovation Research grant to develop noveloligonucleotide backbones. Dyad will develop nuclease resistantoligonucleotide analogues for antisense inhibition of protein synthesis.* Khepri Pharmaceuticals Inc., South San Francisco, received twoSmall Business Innovation Research grants to develop therapeutics forwound healing and neurologic diseases based on proteases and proteaseinhibitors.* SmithKline Beecham's new oral anti-herpes drug, Famvir(famciclovir), is now available in the United States. It is indicated forthe treatment of shingles.* Chiron Corp. Emeryville, Calif., said it was granted a cross-borderpreliminary injunction from a court in the Netherlands against themanufacture, sale and distribution of hepatitis C virus immunoassaysallegedly infringing Chiron's European patent by Organon TeknikaN.V. and United Biomedical Inc., the U.S. company that manufacturesHCV immunoassays for Organon.

(c) 1997 American Health Consultants. All rights reserved.

No Comments